- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 11/14 - Antitussive agents
Patent holdings for IPC class A61P 11/14
Total number of patents in this class: 422
10-year publication summary
|
18
|
39
|
22
|
38
|
43
|
45
|
30
|
32
|
33
|
18
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Glaxosmithkline Intellectual Property (no.2) Limited | 302 |
13 |
| Chiesi Farmaceutici S.p.A. | 959 |
11 |
| Boehringer Ingelheim International GmbH | 4493 |
10 |
| Institute of Materia Medica, Chinese Academy of Medical Sciences | 186 |
9 |
| Wuhan LL Science and Technology Development Co., Ltd | 73 |
9 |
| Genexa Inc. | 32 |
8 |
| The Procter & Gamble Company | 21861 |
7 |
| Biocopea Limited | 21 |
7 |
| Nippon Chemiphar Co., Ltd. | 226 |
7 |
| Daiichi Sankyo Company, Limited | 1893 |
5 |
| Verona Pharma plc | 39 |
5 |
| The First Affiliated Hospital of Guangzhou Medical University | 16 |
5 |
| Guangzhou Institute of Respiratory Disease | 10 |
5 |
| Chengdu Shibeikang Biomedical Technology Co., Ltd. | 31 |
5 |
| Antecip Bioventures II LLC | 374 |
4 |
| Jiangsu Kanion Pharmaceutical Co., Ltd. | 92 |
4 |
| Mochida Pharmaceutical Co., Ltd. | 341 |
4 |
| Shionogi & Co., Ltd. | 873 |
4 |
| Trevi Therapeutics, Inc. | 42 |
4 |
| Salus Pharma Technology (Shanghai) Co., Ltd. | 4 |
4 |
| Other owners | 292 |